



Integra LifeSciences Announces Launch of the Mobius(TM) Multi Modality Monitoring System

PLAINSBORO, N.J., Oct 9, 2006 (PrimeZone Media Network via COMTEX News Network) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced the launch of the Mobius™ Multi Modality Monitoring System as the latest addition to Integra's neuromonitoring product line. The Mobius system has received 510K clearance from the United States Food and Drug Administration (FDA). Integra is featuring the Mobius system at the Congress of Neurological Surgeons Meeting in Chicago this week.

The Mobius™ Multi Modality Monitoring System is designed to complement Integra's existing neuromonitoring product lines by providing a single interface for monitoring multiple neurological and other parameters. The Mobius system serves as a physical and communication hub for existing Integra monitoring systems, such as the Camino® and LICOX® systems that measure intracranial pressure, temperature, and oxygen in the brain, and the patient's bedside monitor. The Mobius system also provides secure data archiving capabilities and multimedia-based instructional content pertaining to the use of Integra's monitoring products.

By connecting their existing monitoring systems to the Mobius system, physicians and clinical staff will be able to simultaneously view, trend, analyze, and archive for study many relevant neuromonitoring parameters, including intracranial pressure (ICP), oxygen (PbtO2), cerebral perfusion pressure (CPP), temperature (ICT), cerebral blood flow (CBT), and systemic arterial pressure (SAP). In addition, the Mobius system provides guidelines and step-by-step, multimedia-driven setup and usage instructions for Integra's extensive neuromonitoring product line, as well as quick reference access to the entire Brain Trauma Foundation guidelines.

"The Mobius Multi Modality Monitoring System allows neurosurgeons, intensivists and other clinicians to extract various acute physiological parameters that impact cerebral oxygenation from the bed-side monitors together with ICP, CPP, brain tissue oxygenation and brain temperature from the neuromonitoring equipment," said Dr. Pradeep Narotam M.D. FACS, Assistant Professor at the Division of Neurosurgery at Creighton University Medical Center. "The Mobius system addresses the constant need to track and review neuro-critical care data in real time during a patient's treatment. The ability to better track and review neuromonitoring data, together with the reference features incorporated into the Mobius system, could translate into clinical benefits to the patient that could lead to improved outcomes in patients with acute neurological disorders, especially traumatic brain injury."

Creighton University Medical Center has been using the Mobius Multi Modality Monitoring System as part of a limited marketing evaluation.

The Mobius Multi Modality Monitoring System will be sold by the Integra NeuroSciences® direct sales organization. Integra NeuroSciences is a leading provider of implants, devices, instruments, and systems used in neurosurgery, neuromonitoring, neuro-trauma, and related critical care. Integra NeuroSciences' direct selling effort in the United States and Europe currently involves more than 150 professionals. In all other markets, Integra NeuroSciences products are sold through a network of distributors.

Integra LifeSciences Holdings Corporation is a diversified medical technology company that develops, manufactures, and markets medical devices for use in a variety of applications. The primary applications for our products are neurosurgery, reconstructive surgery and general surgery. Integra is a leader in applying the principles of biotechnology to medical devices that improve patients' quality of life. Our corporate headquarters are in Plainsboro, New Jersey, and we have manufacturing and research facilities located throughout the world. Please visit our website at <http://www.Integra-LS.com>.

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the potential use of the Mobius Multi Modality Monitoring System. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of physicians to use the Mobius system may affect the prospects for its use in clinical procedures. In addition, the economic, competitive, governmental, technological and other factors identified under the heading "Factors That May Affect Our Future Performance" included in the Business section of Integra's Annual Report on Form 10-K for the year ended December 31, 2005 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.

This news release was distributed by PrimeZone, www.primezone.com

SOURCE: Integra LifeSciences Holdings Corp.

Integra LifeSciences Holdings Corporation

John B. Henneman, III, Executive Vice President and Chief Administrative Officer

(609) 936-2481

jhenneman@Integra-LS.com

John Bostjancic, Vice President, Corporate Development and Investor Relations

(609) 936-2239

jbostjancic@integra-LS.com